Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Finn Gustafsson
With
Rigshospitalet, Denmark
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 years
Left ventricular ejection fraction (LVEF) \< 45 % on the baseline echocardiography.
Treatment with beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors for at least 1 month as tolerated
New York Heart Association (NYHA) Functional Class II-III
Given informed consent
Women, who have not yet entered menopause (defined as no menstrual bleeding in the last 12 months), will provide a negative urine HCG before entering the study
You may not be if
Signs of symptomatic or ongoing myocardial ischemia
Known non-revascularized coronary disease
Presence of hypovolemic hyponatremia (P-Na+ \<130 mmol/l and clinical signs of volume depletion or dehydration as judged by investigator).
Standing blood pressure \< 80 mmHg or a blood pressure drop \> 20 mmHg when changing from a supine to a standing position
Uncontrolled hypertension evaluated by the investigator
Uncontrolled cardiac arrhythmias evaluated by the investigator
Untreated serious hypothyroidism
Adrenal insufficiency
Poor echocardiographic window
Inability to perform exercise testing
Permanent atrial fibrillation or atrial fluttering
Planned coronary by-pass surgery
Moderate hepatic impairment (ALAT/ASAT \> 3 UNL)
Presence of other diseases affecting treatment with conivaptan or the evaluation of safety as evaluated by the investigator
Severely decreased kidney function (eGFR \< 20 mL/min)
Serum K+\< 3.5 or \> 5.5 mmol/L
Known conivaptan intolerability
Corn allergy
Dextrose Allergy
Treatment with potent CYP3A-inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir)
Treatment with arginine vasopressin, oxytocin, desmopressin and other medications for the treatment of hyponatremia (lithium salts, urea and demeclocycline)
Warfarin treatment
Presence of infection or active bleeding
Clareo Health | Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients
